About

Zixuan is the Vice President at IDG Capital. He focuses on early-stage biotech investments, new modality, and disruptive biotechnologies.

Before becoming the Vice President, Zixuan served as Associate at IDG Capital in Beijing, dealing sourcing, research, and led a few investments in the biotech sector. 

Zixuan received his Ph.D. in Philosophy, Neuroscience, Dermatology, and Biochemistry from the Johns Hopkins University School of Medicine, and Bachelor of Science in Biology, Bachelor of Arts in International Politics from Peking University.

Fred Dom is one of the original founders and Chief Executive Officer of HiFiBiO Therapeutics. He is a serial entrepreneur with expertise in private capital investment and biotech formation in the Netherlands, France, and US. Fred holds board positions in Calyxia (France), Kapsera (France) and Oncode Accelerator (Dutch public-private initiative with €325 million funding from National Growth Fund), and he is a member of the Advisory Board of Dutch Life Science and Health industry.

Previously, Fred was Chief Executive Officer and co-founder of Saber Bio (created in 2021), which was acquired by a world leading life science tools company in 2024. Before Saber, Fred held CEO and CFO positions at HiFiBiO Therapeutics.

Fred holds a B.Sc. and M.Sc. in economics from the Erasmus University in Rotterdam, the Netherlands.

HyoJeong Kim is the Healthcare Team Manager for Mirae Asset Capital, managing investments in the healthcare industry. Her portfolio includes notable companies such as inSilico Medicine, Sonoma Biotherapeutics, and Akili Interactive.

Prior to Mirae Asset, HyoJeong was a Venture Capitalist at SpringCamp focusing on early-stage startups. Before SpringCamp, HyoJeong was Marketing Manager at Janssen Korea. HyoJeong holds a B.A. in Pharmacy from Seoul National University.

Cheryle Cui is a Partner at Nest.Bio Ventures and CEO of Bota.

She was a former Venture Partner at VentureHealth, a Silicon Valley-based healthcare fund, where she coordinated portfolio companies’ growth strategy in the Asia Pacific. Cheryl previously co-founded a mobile health company that facilitates the care of Alzheimer’s patients, which was successfully acquired in 2012 and led to her selection as one of Canada’s Next 36. She currently serves as a Board Member of Rootpath and HiFiBio Therapeutics.

Cheryl earned her joint PhD degree in Medical Engineering and Medical Physics from MIT and Harvard Medical School and her B.A.Sc. in Engineering Science and Biomedical Engineer from the University of Toronto.

Lynn Yang is a Partner at HongShan, focusing on the healthcare sector, where she has led investments in numerous renowned healthcare enterprises.

Prior to joining HongShan in 2015, she worked at Legend Capital healthcare team. Previously, Lynn Yang served as a Business Development Manager and Product Manager at major multinational companies such as Johnson & Johnson and GE Healthcare.

She holds an MBA from Duke University in the United States and a master’s degree in clinical medicine from Tongji Medical College of Huazhong University of Science and Technology.